Dipeptidyl peptidases (DPPs) are proteolytic enzymes that are ideal therapeutic targets in human diseases. Indeed, DPP4 inhibitors are widely used in clinical practice as anti-diabetic agents. In this paper, we show that DPP4 inhibitors also induced cell death in multiple human myeloma cells. Among five DPP4 inhibitors, only two of them, vildagliptin and saxagliptin, exhibited apparent cytotoxic effects on myeloma cell lines, without any difference in suppression of DPP4 activity. As these two DPP4 inhibitors are known to have off-target effects against DPP8/9, we employed the specific DPP8/9 inhibitor 1G244. 1G244 demonstrated anti-myeloma effects on several cell lines and CD138+ cells from patients as well as in murine xenograft model. Through siRNA silencing approach, we further confirmed that DPP8 but not DPP9 is a key molecule in inducing cell death induced by DPP8/9 inhibition. In fact, the expression of DPP8 in CD38+ cells from myeloma patients was higher than that of healthy volunteers. DPP8/9 inhibition induced apoptosis, as evidenced by activated form of PARP, caspases-3 and was suppressed by the pan-caspase inhibitor Z-VAD-FMK. Taken together, these results indicate that DPP8 is a novel therapeutic target for myeloma treatment.
T-anaplastic large cell lymphoma 30, 31 and multiple myeloma 32 are also potential targets of CD26-directed therapies as well as MPM and RCC.
Therefore, herein we initially investigated the therapeutic efficacy of DPP4 inhibitors on multiple myeloma cells, work which subsequently led to the interesting findings indicating that DPP8 is a novel therapeutic target for multiple myeloma.
Results
Cytotoxic effects of DPP4 inhibitors against multiple myeloma cell lines. The cytotoxic effects of DPP4 inhibitors on multiple myeloma cell lines were examined using WST-1 cell proliferation assay system as shown in Fig. 1A . Vildagliptin treatment up to 100 µM led to decreased cell number of MM.1 S or RPMI8226 cells in a concentration-dependent manner till 7 and 70%, respectively. Nevertheless, 100 µM of vildagliptin is not achieved as a plasma concentration by the recommended oral daily dose (i.e. 100 mg) since oral administration of 200 mg of vildagliptin resulted in less than 5.0 µM of plasma concentration as demonstrated previously 33 . Similar cytotoxic effects were observed when cells were treated with saxagliptin; however, both cell lines were unaffected in the presence of sitagliptin, alogliptin, or linagliptin. As only vidagliptin and saxagliptin showed the marked cytotoxicity ( Fig. 1B) , it was assumed that the cytotoxicity of those two DPP4 inhibitors was due to stronger suppressive effects on DPP4 activity than the other three DPP4 inhibitors. However, surprisingly, the suppressive effects of these five DPP4 inhibitors on DPP4 activity were almost identical (Fig. 1C ). In addition, the cytotoxic effects against the T-cell lymphoma cell line Karpas 299 was also observed only with vildagliptin and saxagliptin. ( Supplementary Fig. 1A ). These results indicated that vildagliptin and saxagliptin exerted their anti-myeloma activity by other mechanisms than DPP4-inhibition.
Anti-myeloma activity of DPP8/9 inhibitor. Based on previous work showing that vildagliptin and saxagliptin were classified into the same category (Class 1) of DPP4 inhibitors 34 and had non-negligible off-target effects on DPP8/9 activity 35 , we hypothesized that vildagliptin and saxagliptin-induced inhibitory effects on DPP8/9 were the causal factor for their anti-myeloma activity. To further address this topic, we employed a specific DPP8/9 inhibitor, 1G244 36 to confirm whether DPP8/9 inhibition actually induced cell death in multiple myeloma cells. As shown in Fig. 2A , 1G244 dose-dependently decreased viable cell number of five multiple myeloma cell lines as well as three T-cell lymphoma cell lines ( Supplementary Fig. 1B ). Almost complete cell death of all cell lines was observed at a dose of 100 µM. However, since it is known that 100 µM of 1G244 induced nonspecific cell death 37 ; we therefore used 1G244 at levels below 50 µM in our subsequent experiments. Since, MM.1 S was the most susceptible among five cell lines, it was inoculated into mice to confirm the anti-myeloma effects of 1G244 in vivo. 1G244 was administered subcutaneously into mice at 30 mg/kg once a week, since daily intravenous injection of 1G244 at the same dosage has been linked to severe cyanosis in rats on day 4 or 5 36 .
Once-a-week administration of 1G244 apparently suppressed the subcutaneous growth of MM.1 S cells with no other obvious clinical symptoms in mice ( Fig. 2B ). 1G244 effect on samples from patients with multiple myeloma was also examined. CD138-positive myeloma cells were efficiently isolated from bone marrow cells using magnetic beads ( Supplementary Fig. 2 ). Myeloma cells of all five patients were regarded as non-viable (91-97%) following incubation with 50 µM 1G244 ( Fig. 2C ). It should be noted that myeloma cells of patient 2 had a deletion of chromosome 17p, being resistant to various chemotherapeutic and biologic agents such as bortezomib, lenalidomide, dexamethasone, cyclophosphamide, and doxorubicin. These results suggested that DPP8/9 inhibition induced cell death in myeloma cells via a distinctive signaling pathway which did not overlap with that of existing chemotherapeutic and biologic agents. Therefore, the effect of the combination of 1G244 and bortezomib was examined ( Fig. 2D ). 1G244 at a dose of 0.5 µM displayed no cytotoxic effects on MM.1 S cells; however, in combination with bortezomib (20 nM), the number of viable cells decreased significantly compared to the effect of bortezomib (20 nM) alone. Similar effects were observed on another myeloma cell line, KMS-5. These results suggested that DPP8/9 is a realistic potential therapeutic target for the management of multiple myeloma; however, it was reported that the cell death of THP-1 monocytes induced by 1G244 was not dependent on DPP8/9 38 . Therefore, we introduced small interfering RNAs (siRNAs) into our experiments to downregulate specifically the expression of either DPP8 or DPP9.
DPP8 as a target of myeloma therapy. In order to determine whether DPP8 or DPP9 is particularly responsible for the anti-myeloma activity of 1G244, we employed small interfering RNAs (siRNAs) specific to either DPP8 or DPP9, due to unavailability of specific chemical inhibitors to either DPP8 or DPP9 since these two DPPs closely resemble each other in structure 39, 40 . As shown in Fig. 3A , treatment with siRNAs specific to DPP8 clearly decreased viable cell number; however, treatment with siRNA specific to DPP9 showed no such change.
These results indicated that DDP8 is a novel target for myeloma therapy. Indeed, DPP8 was expressed at a higher level in CD38+ bone marrow cells of Waldenstrom's macroglobulinemia and multiple myeloma patients than those of healthy volunteers ( Fig. 3B ). Regarding the potential cellular mechanism involved in 1G244-induced cell death in multiple myeloma cells, apoptosis was the most likely, as cleaved forms of both caspase-3 and PARP were detected ( Fig. 3C ). Furthermore, 1G244-induced cell death was suppressed by the pan-caspase inhibitor Z-VAD-FMK (Fig. 3D ). These findings led to our conclusion that the mechanism for cell death of multiple myeloma cells induced by DPP8-inhibition is apoptosis.
Discussion
Recently, inhibition of DPP8/9 has garnered attention as a new potential therapeutic strategy for acute myeloid leukemia (AML). Johnson DC et al. reported that Val-boroPro, a non-selective inhibitor of the post-proline cleaving serine proteases, as well as the specific DPP8/9 inbibitors 1G244 and L-allo-Ile-isoindoline induced cell death in many AML cell lines and primary AML samples 37 . Although it was demonstrated that Val-boroPro had no activity against any of the non-AML cell lines, it did not necessarily contradict our findings that DPP8/9 inhibition induced cell death in multiple myeloma cells. This is due to the fact that the twenty non-AML cell lines which were tested did not include multiple myeloma cell lines. Therefore, our present paper reports for the first time the anti-myeloma activity induced by the DPP8/9 inhibitor. Meanwhile, Johnson DC et al. concluded that pyroptosis, an immunostimulatory form of programmed cell death, was the mechanism responsible for cell death induced by the DPP8/9 inhibition, being dependent on caspase-1 activation downstream of inflammasome formation 37 . In their report, caspase-1 expression was found as a key determinant of cell sensitivity to a DPP8/9 inhibitor and that treatment of sensitive cells with a DPP8/9 inhibitor induced the cleavage of pyroptotic substrate gasdermin D (GSDMD) but not the apoptotic substrate PARP. However, in contrast, our data showed that caspase-3 and PARP cleavage was clearly detected in 1G244-mediated cell death of multiple myeloma cells (Fig. 3C) . We thus concluded that apoptotic cell death signaling was induced in multiple myeloma cells by DPP8/9 inhibition. Our conclusion does not completely oppose the possible involvement of pyroptotic cell death because cell death signaling involves a complex process. The inflammasome formation can activate caspase-8, which mediates the activation of downstream caspases such as www.nature.com/scientificreports www.nature.com/scientificreports/ caspase-3, caspase-7, and caspase-9 [41] [42] [43] . Besides, caspase-3 can be activated downstream of caspase-1 through inflammasome responses independent of caspase-8 44 . In the case of 1G244-dependent caspase-3 cleavage, additional detailed work is required to examine the potential involvement of inflammasome responses.
During the investigation of DPP8/9 inhibition-induced pyroptotic cell death signaling of AML cells, caspase recruitment domain-containing protein 8 (CARD8) was identified as an activator of pro-caspase-1 37 . Concerning the mechanism involved in DPP8/9 inhibition-mediated activation of CARD8, DPP9 was regarded as a novel interacting partner with CARD 8 as well as the NLR family member, pyrin domain containing 1 (NLRP1) 45 . NLRP1 is the human homolog of the mouse Nlrp1b, which is activated in murine macrophage cells treated with the DPP8/9 inhibitors 46 . DPP9 functions as an endogenous inhibitor of NLRP1; therefore, DPP8/9 inhibition activates NLRP1, leading to pyroptotic cell death. Interestingly, DPP9 contributes to the inhibition of NLRP1 not only by its catalytic function but also by physical interaction with NLRP1. These findings are based on the data showing that the catalytically inactive DPP9 point mutant S759A, which does not compromise the ability of DPP9 to bind NLRP1, led to significant but partial repression of NLRP1-dependent pyroptosis reaction, and DPP8/9 inhibitors caused the dissociation of DPP9 from NLRP1. While the inhibitory mechanism of DPP9 on NLRP1-dependent pyroptosis by its physical interaction with NLRP1 needs to be investigated further, it is important to note that some other biological function of DPP9 other than its catalytic activity may be revealed in the future.
While either CARD8 or NLRP1 may be involved in DPP9-dependent pyroptosis, a mechanism involved in DPP8-induced apoptotic cell death has not yet been elucidated. The catalytic activity of DPP8 is the most probable function that contributes to the induction of apoptotic cell death signaling; however, other possible involvement of its non-catalytic function such as protein interaction may also play a role.
In the present study, we speculate that its inhibitory effect on DPP8/9 is responsible for the anti-myeloma activity of vildagliptin; however, "off-target" effects should be taken into consideration when vildagliptin is used as an anti-cancer drug. Regarding this point, recent investigation demonstrated that vildagliptin reduced lung cancer growth exerted by surfactant-activated macrophages and NK cells via tumor necrosis-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity 22 .
In summary, our present work demonstrated that DPP8 is a novel target for multiple myeloma therapy inducing apoptotic cell death. Further development of specific inhibitors against DPP8 would provide promising therapeutic effects in human multiple myeloma. 
Methods

Reagents. Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD-FMK) was purchased from
Medical and Biological Laboratories (Nagoya, Japan). 1G244 was purchased from AK Scientific (Union city, CA). Alogliptin was purchased from ChemScene (Monmouth Junction, NJ). Linagliptin was purchased from BioVision (Milpitas, CA). Sitagliptin and Bortezomib were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Vildagliptin was purchased from LKT Laboratories (St. Paul, MN). Saxagliptin was purchased from Adooq Bioscience (Irvine, CA). Cellular cytotoxicity. The number of viable cells seeded onto a 96-well culture plate was quantified using Premix WST-1 Cell Proliferation Assay System (TaKaRa, Kyoto, Japan) according to the manufacturer's instructions. Briefly, 10 μl of Premix WST-1 per 100 μl of culture medium was added to each well and the cells were incubated under the standard culture condition for 1 hour. WST reduction was determined with an automated ELISA plate reader, ImmunonMini NJ-2300 spectrophotometer (InterMed, Tokyo, Japan), at an optical density (OD) of 450-650 nm, as we described previously 47 . In vivo studies. NOD/Shi-scid IL-2Rγnull (NOG) female mice of age (6-7 weeks) and weight (19-21 g) were obtained from Central Institute for Experimental Animals (CIEA) (Kawasaki, Japan). The mice were kept under specific pathogen-free conditions with a 12 hour day and night cycle with free access to food and water, and received humane care in compliance with Institutional Guidelines. All experiments were approved by the Animal Care and Use Committee of Sapporo Medical University and were performed in accordance with the guidelines and regulations of the Animal Care and Use Committee of Sapporo Medical University. In order to examine the anti-myeloma activity of 1G244, 5 × 10 6 MM.1 S cells were inoculated subcutaneously on the left side at the back of NOG mice. Three days after the inoculation, 30 mg/kg of 1G244 was administered subcutaneously once-a-week. The growth of tumor was followed every third or fourth day by measurements with a caliper and its volume was calculated according to the following formula: MD × TL 2 × 1/2, where MD and TL are the maximum diameter and transverse length, respectively. The mice were sacrificed before the volume of the tumor mass reached 3,500 mm 3 for ethical reason, as we described previously 30 . Western blot analyses. Cells were lysed in a buffer containing 1% sodium dodecyl sulfate (SDS), 20 mM Tris-HCl pH 7.4, 5 μg/ml pepstatin A, 10 μg/ml leupeptin, 5 μg/ml aprotinin and 1 mM phenyl-methylsulfonyl fluoride and then heated for 5 minutes. After passage through a 20-gauge needle ten times and centrifugation at 15,000 rpm at 4 °C for 30 minutes, the aliquot was boiled in a standard reducing sample buffer for 3 minutes and subjected to SDS-polyacrylamide gel electrophoresis. It was followed by transfer to Immobilon-P membrane (Millipore, Bedford, MA) and hybridization with anti-poly (ADP-ribose) polymerase (PARP) antibody (#9542) (Cell Signaling, Danvers, MA), anti-caspsae-3 antibody (#9662) (Cell Signaling), and anti-actin antibody (sc-1615) (Santa Cruz Biotechnology). Proteins detected by these antibodies were visualized with horseradish peroxidase-conjugated anti-rabbit or goat antibody (Santa Cruz Biotechnology) followed by the use of enhanced chemiluminescence (Amersham Pharmacia Biotech, Uppsala, Sweden), as we described previously 47 .
Gene expression database. A dataset record GDS2643 was found in the Gene Expression Omnibus
Statistical analysisn. The statistical significance of difference was evaluated by Student's t-test using
GraphPad Prism version 5.0 (GraphPad Software, La Jolla, CA). Statistical significance of p < 0.05 considered significant.
